Press Detail

/
PRESS RELEASE

Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group

Dreieich, 1 June, 2017. Today, the Management Board and Supervisory Board of Biotest AG published their joint reasoned statement, pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz - WpÜG), in respect of the offer document published by Tiancheng (Germany) Pharmaceutical Holdings AG, the bidding company of CREAT Group, on 18 May 2017.

In this statement, following a due process of review, the Management Board and Supervisory Board recommend that shareholders accept the offer. This recommendation is explained in further detail in the joint reasoned statement.

Following an in-depth appraisal, the Management Board and Supervisory Board have independently formed the opinion that the consideration offered by the Bidder is fair within the meaning of Section 31 para. 1 WpÜG and that the implementation of the Offer is in the interest of Biotest and its shareholders In assessing the fairness of the offer consideration from a financial point of view, the Management Board and Supervisory Board were advised by Credit Suisse, which has issued a written Fairness Opinion in which it concludes that the offer price for Biotest shareholders is fair to such shareholders from a financial point of view.

Especially in light of the recent operational challenges and the difficult transition period during the implementation of the Biotest Next Level (BNL) strategy, Biotest's Management Board and Supervisory Board welcome Creat's offer and believe it represents attractive value for shareholders of both share classes. Together with Creat, Biotest aims to strengthen and expand its global competitiveness by continuing to develop new products, further pursuing existing projects such as Biotest Next Level (BNL) as well as by strengthening its international presence.

The complete joint reasoned statement by the Management Board and the Supervisory Board of Biotest AG can be accessed via the following link: http://www.biotest.com/de/en/investor_relations/takeover-offer.cfm

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.